Kun for helsepersonell
ZAVICEFTA has a similar safety and tolerability profile in paediatric patients aged 3 months and older to that observed in adults1–3
The most common adverse reactions (>3%) for ZAVICEFTA were vomiting, diarrhoea, rash and infusion-site
There were low rates of discontinuation due to adverse effects and no deaths were reported in either study2,3
The safety assessment in paediatric patients is based on data from two trials in which 61 patients with cIAI and 67 patients with cUTI aged 3 months to
<18 years received ZAVICEFTA.1–3
Learn more about ZAVICEFTA’s dosing in adult and paediatric patients.
cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection.
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.